real-time news and commentary for investors
Monday, Feb 4
Merck (MRK -1.9%) moves lower on a couple of downgrades today one from Morgan Stanley to...
Merck (MRK -1.9%) moves lower on a couple of downgrades today one from Morgan Stanley to underweight and another from Leerink Swann to Market Perform. Morgan, who seems to be having the biggest adverse affect on the shares today, saying there's 75% chance that the large "Improve-It" study of its cholesterol drug Vytorin will fail. If that's the case, the stock could decline by double-digits on a percentage basis. Leerink cites uncertainty around odanacatib, as well as increasing competition for Januvia and Isentress as its motive for cutting the shares.